A drug currently used to treat osteoporosis has shown promise in blocking spinal damage in a recent study. The research, conducted using zebrafish, found that altered gene activity can lead to mineral accumulation in the spine. This process hardens spinal tissue and resembles bone formation in unintended areas.
Researchers observed that zebrafish bred with a faulty collagen-related gene developed spinal abnormalities. These included fused vertebrae and mineral deposits that made the tissue between bones abnormally hard. This condition closely mirrored intervertebral disc degeneration (IVDD) in humans.
The study identified that the mineralization did not occur immediately. It followed the deterioration of a supportive scaffold layer within the developing spine. Analysis of gene activity in the fish revealed issues with fat processing, the mTOR pathway regulating growth, phosphate control, and vitamin A signaling. These processes are all linked to abnormal mineral accumulation.
Several methods reduced the spinal damage in the zebrafish. A bisphosphonate, an osteoporosis medication, prevented mineral buildup. Reducing food intake or administering drugs that suppressed fat metabolism also decreased spinal fusion. These findings suggest that phosphate regulation and fat metabolism are promising targets for new treatments.
Intervertebral disc degeneration is a major cause of back pain. No medications currently exist to stop or reverse its progression. This discovery points to potential new therapeutic approaches beyond surgical intervention. The study was funded by Arthritis UK and BBSRC and published in *Communications Biology*.
Related stories
Osteoporosis Drug May Prevent Spinal Damage in Zebrafish Study
A study using zebrafish found that an existing osteoporosis drug could prevent spinal damage, offering a new path for treating back pain.
Compound Strengthens Bones in Mice, Offers Osteoporosis Treatment Hope
Scientists found that an experimental compound, AP503, strengthened bones in mice by activating the GPR133 receptor, offering a new approach to fight osteoporosis.
Compound Strengthens Bones and Muscles in Mice
A new compound, AP503, has been shown to strengthen bones and muscles in mice by activating the GPR133 receptor, offering potential for osteoporosis treatment.